ArticleAnnals of clinical microbiology and antimicrobials2026
Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis.
Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is a significant fungal pathogen responsible for allergic bronchopulmonary aspergillosis (ABPA), a global respiratory disease characterized by high morbidity and mortality. Accurate diagnosis of ABPA remains challenging due to the overlap of clinical and radiological features with other respiratory infections. This study aimed to identify A. fumigatus specific antigens and epitopes to advance immunodiagnostic and immunotherapeutic strategies for ABPA. Clinically confirmed ABPA patients were recruited, and their sera were tested for immunoreactivity against A. fumigatus crude and recombinant allergens. Proteomic analysis was done by employing two-dimensional electrophoresis (2DE) immunoblotting of A. fumigatus cytosolic fractions using sera from 10 individual patients. IgE-reactive spots identified via Q-TOF mass spectrometry revealed 18 allergenic proteins. Among these, two known allergens (Asp-f12 and Asp-f22) and three predicted allergens (sorbitol/xylulose-reductase, Hsp70-chaperone Hsp88, and Hsp70) exhibited cross-reactivity with allergens from other fungi. Notably, 13 allergenic proteins demonstrated significant immunoreactivity specific to ABPA patient sera. In silico epitope analysis identified 9 A. fumigatus specific B-cell and 4 T-cell epitopes with antigenic potential. Molecular docking studies confirmed the binding of representative B-cell and T-cell epitopes to their respective receptors (B-cell receptor and MHC-II complex), demonstrating receptor-specific interactions. These findings highlight pathogen-specific allergens and epitopes that could serve as valuable resources for developing targeted immunodiagnostic and immunotherapeutic tools. This approach may improve the clinical management of ABPA and help reduce its global disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.